Health Products

Sanofi-Aventis Avalide Product Recall(2021-06-14)

· Published by Health Canada · Official notice

Details

Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I

Summary

Product

A. Avalide 300-12.5 mg

Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberCompaniesBrand nameDIN, NPN, DIN-HIMDosage formStrength
ET02879, FT01327
Recalling Firm
Sanofi-Aventis Canada Inc.
2905 Place Louis.R-Renaud
Laval
H7V 0A3
Quebec
CANADA
Marketing Authorization Holder
Sanofi-Aventis Canada Inc.
2905 Place Louis.R-Renaud
Laval
H7V 0A3
Quebec
CANADA
B. Avalide 150-12.5 mgDIN 02241818TabletIrbesartan 150 mg
FT01644
Recalling Firm
Sanofi-Aventis Canada Inc.
2905 Place Louis.R-Renaud
Laval
H7V 0A3
Quebec
CANADA
Marketing Authorization Holder
Sanofi-Aventis Canada Inc.
2905 Place Louis.R-Renaud
Laval
H7V 0A3
Quebec
CANADA
A. Avalide 300-12.5 mgDIN 02241819TabletIrbesartan 300 mg

Reason

Presence of impurity 5-(4-(azidomethyl)-[1,1-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration
limit in affected lot.

Depth of distribution

Retailers, Other (healthcare practioners)
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime